High quality and representative gonococcal antimicrobial resistance (AMR) data is imperative to monitor AMR trends, identify emerging AMR, and inform refinements of global, international and national clinical management guidelines and public health policies. The WHO Global Gonococcal Antimicrobial Surveillance Program (GASP) has been documenting the emergence and spread of AMR in gonorrhea globally since 1992.
The GASP is a worldwide laboratory network coordinated by focal points and regional coordinating centres. Each designated regional focal point, in partnership with its WHO regional office, collates data on patterns of antimicrobial susceptibility in gonorrhoea in participating countries.
In order to have accurate and comparable data globally and detect emerging resistance, gonococcal culture-based AMR monitoring needs to be standardized and linked to clinical and epidemiological data. To address these needs, the Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP) was initiated.
EGASP is a focused sentinel surveillance, where men presenting with urethral discharge are consecutively identified in sentinel sites and clinics. Demographic, clinical, and behavioral data are collected during routine clinical activities and urethral specimens are processed in selected reference laboratories using quality-assured culture techniques and MIC determination. Laboratory and epidemiological data are combined, validated, analyzed, and shared with WHO through a dedicated EGASP module in the GLASS-IT platform. Tools are available to facilitate the implementation and expansion of EGASP including the generic EGASP protocol.
Scientific articles
Globally, more than 1 million curable sexually transmitted infections (STIs) occur each day. According to WHO global estimates for 2016, there were roughly...
Gonorrhoea is a major public health challenge today, due to the high incidence of infections accompanied by a dwindling number of treatment options. The...